A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
Jose Mourinho is struggling to adapt to life in Manchester after taking the manager's job at Old Trafford this summer.
'Flushable' wet wipes are blighting beaches and blocking sewers, costing water companies and tax payers more than £80 million a year.
Two young children who survived the theme park ride crash in Australia reportedly watched helplessly as their mothers were killed.